% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Apr 2, 2014 1:41 PM Flag

    RCC: Benchmarks for Trial Design (IMDC)

    From the current edition of the BJC, JJ Ko et al...T Choueiri is a co-author. This article comes up with a site search for Cabo, and Doc Choueiri's affiliation is - of course - well known as a Meteor investigator. The survival numbers below are an excerpt from the abstract, some of which will likely reflect upon Choueiri's take on Cabo as Meteor data comes to maturity. To the best of my knowledge, this publication constitutes the latest posting of survival data relative to RCC trial interpretation. Might be valuable to have around...
    In total, 2705 patients were treated with TT of which 57% received only first-line TT, 27% received two lines of TT, and 16% received 3+ lines of TT. Overall survival of patients who received 1, 2, or 3+ lines of TT were 14.9, 21.0, and 39.2 months, respectively, from first-line TT (P

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Wilder, English please? What does TT have to do with Cabo? Are you inferring that the more times you receive the drug (3+line) the greater the OS benefit and is the drug you're talking about Cabo?

      Sentiment: Strong Buy

      • 2 Replies to enabeler
      • TT = Targeted therapy

      • $$$$
        TT= targeted therapy. The relevance to cabozantinib is inferred but based upon the fact that Cabo is in P3 trial in this indication, the lead investigator in that Cabo trial is a coauthor of the publication, and the information contained therein constitutes the latest available information that will likely be considered to determine Meteor trial success. Lots of good OS & PFS analysis here...
        As the article is directed toward 1st, 2nd, and 3rd line TT, it excludes the therapeutic interventions of surgery, radiation, cytotoxic chemo, etc... So - with that in mind - yes, the trial interpretation information available in this abstract is pertinent to Cabo, as it is a targeted therapeutic available in RCC through the clinical trial process.

6.065-0.025(-0.41%)12:14 PMEDT